These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 15245774)
1. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Kemper EM; Boogerd W; Thuis I; Beijnen JH; van Tellingen O Cancer Treat Rev; 2004 Aug; 30(5):415-23. PubMed ID: 15245774 [TBL] [Abstract][Full Text] [Related]
2. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). van Vulpen M; Kal HB; Taphoorn MJ; El-Sharouni SY Oncol Rep; 2002; 9(4):683-8. PubMed ID: 12066192 [TBL] [Abstract][Full Text] [Related]
3. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. Gerstner ER; Fine RL J Clin Oncol; 2007 Jun; 25(16):2306-12. PubMed ID: 17538177 [TBL] [Abstract][Full Text] [Related]
4. Blood-brain barrier disruption in the treatment of brain tumors. Blanchette M; Fortin D Methods Mol Biol; 2011; 686():447-63. PubMed ID: 21082387 [TBL] [Abstract][Full Text] [Related]
5. Drug delivery to brain tumours: challenges and progress. Ningaraj NS Expert Opin Drug Deliv; 2006 Jul; 3(4):499-509. PubMed ID: 16822225 [TBL] [Abstract][Full Text] [Related]
6. Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. Erdlenbruch B; Jendrossek V; Kugler W; Eibl H; Lakomek M Cancer Chemother Pharmacol; 2002 Oct; 50(4):299-304. PubMed ID: 12357304 [TBL] [Abstract][Full Text] [Related]
7. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Neuwelt EA; Rapoport SI Fed Proc; 1984 Feb; 43(2):214-9. PubMed ID: 6692941 [TBL] [Abstract][Full Text] [Related]
8. [Pharmacologic bases of chemotherapy of brain tumors in children]. Vassal G Bull Cancer; 1990; 77(7):699-713. PubMed ID: 2207360 [TBL] [Abstract][Full Text] [Related]
9. Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters. Emerich DF; Snodgrass P; Dean R; Agostino M; Hasler B; Pink M; Xiong H; Kim BS; Bartus RT Br J Cancer; 1999 Jun; 80(7):964-70. PubMed ID: 10362103 [TBL] [Abstract][Full Text] [Related]
10. Blood-brain barrier and treatment of central nervous system tumors. Wiranowska M J Fla Med Assoc; 1992 Oct; 79(10):707-10. PubMed ID: 1460453 [TBL] [Abstract][Full Text] [Related]
11. Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Fine RL; Chen J; Balmaceda C; Bruce JN; Huang M; Desai M; Sisti MB; McKhann GM; Goodman RR; Bertino JS; Nafziger AN; Fetell MR Clin Cancer Res; 2006 Oct; 12(19):5770-6. PubMed ID: 17020983 [TBL] [Abstract][Full Text] [Related]
12. The blood-brain barrier disruption controversy: does it hold water? Ruffer JE; Glatstein E Cancer J Sci Am; 1998; 4(2):84-5. PubMed ID: 9532409 [No Abstract] [Full Text] [Related]
13. Intravenous cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival. Bartus RT; Snodgrass P; Marsh J; Agostino M; Perkins A; Emerich DF J Pharmacol Exp Ther; 2000 Jun; 293(3):903-11. PubMed ID: 10869391 [TBL] [Abstract][Full Text] [Related]
14. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378 [TBL] [Abstract][Full Text] [Related]
15. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors. Neuwelt EA; Hill SA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Lewis SE; Ehle AL; Beyer CW Cancer Treat Rep; 1981; 65 Suppl 2():39-43. PubMed ID: 6809316 [TBL] [Abstract][Full Text] [Related]
16. [Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas]. Heimberger K; Samec P; Podreka I; Binder H; Suess E; Reisner T; Deecke L; Steger G; Hiesmayr M; Dittrich C Wien Klin Wochenschr; 1987 May; 99(11):385-8. PubMed ID: 3113082 [TBL] [Abstract][Full Text] [Related]
17. Model for drug uptake by brain tumors: effects of osmotic treatment and of diffusion in brain. Robinson PJ; Rapoport SI J Cereb Blood Flow Metab; 1990 Mar; 10(2):153-61. PubMed ID: 2303532 [TBL] [Abstract][Full Text] [Related]
18. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648 [TBL] [Abstract][Full Text] [Related]
19. Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium. Doolittle ND; Abrey LE; Ferrari N; Hall WA; Laws ER; McLendon RE; Muldoon LL; Peereboom D; Peterson DR; Reynolds CP; Senter P; Neuwelt EA Clin Cancer Res; 2002 Jun; 8(6):1702-9. PubMed ID: 12060607 [TBL] [Abstract][Full Text] [Related]
20. Blood-brain barrier and chemotherapeutic treatment of brain tumors. de Vries NA; Beijnen JH; Boogerd W; van Tellingen O Expert Rev Neurother; 2006 Aug; 6(8):1199-209. PubMed ID: 16893347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]